Default Category
-
Evaluating an Investment in Expansion (Spanish version)
Stafford, Erik; Heilprin, Joel L.; DeVolder, JeffreyCase HBS-411S17FinanceWhen students have the English-language PDF of this Brief Case in a coursepack, they will also have the option to purchase an audio version. A manufacturer of private-label personal care products must decide whether to fund an unprecedented expansion of manufacturing capacity. The decision prompts fundamental financial analysis of the potential project, including development of cash flow projections and net present value calculations. Students wi...Starting at €8.20
-
U.S. Healthcare Reform: Reaction to the Patient Protection and Affordable Care Act of 2010
Daemmrich, Arthur A.Case HBS-711103-EEconomicsSupplement to "U.S. Healthcare Reform: International Perspectives," HBS No. 710-040, updating key events and disputes concerning the reform law, including the 2010 Congressional elections, legislative proposals, legal challenges, and responses by employers.Starting at €8.20
-
Grantham, Mayo, and Van Otterloo, 2012: Estimating the Equity Risk Premium
Hanson, Samuel G.; Stafford, Erik; Viceira, Luis M.Case HBS-213051-EFinanceStarting at €8.20
-
Lin TV Corp
Scharfstein, David S.; Stafford, Erik; Heilprin, Joel L.Case HBS-213065-EFinanceThis case considers the valuation of Lin TV, a publicly-traded company with 30 TV stations. The case highlights how a change in operating strategy can enhance the firm's value, and considers the effect of consolidation within the industry on firm value.Starting at €8.20
-
A Managerial Perspective on Clinical Trials
Daemmrich, Arthur A.Case HBS-709033-EEntrepreneurshipThis note describes the history and regulation of clinical trials, managerial challenges related to pharmaceutical product testing, and current debates regarding prescription drug safety. Since clinical testing takes between five and seven years, and consumes up to 70 percent of a drug's total development costs, pharmaceutical and biotechnology leaders need to understand clinical trial management. Likewise, with a growing variety of new product i...Starting at €8.20
-
Targanta Therapeutics: Hitting a Moving Target, Teaching Note
Daemmrich, Arthur A.Teaching Note HBS-710006-EEntrepreneurshipTeaching Note for [709002].Starting at €0.00
-
Arcadia Biosciences: Seeds of Change (Abridged)
Daemmrich, Arthur A.Case HBS-711050-EArcadia Biosciences is seeking to introduce genetically modified rice to China that will lower farmers' costs and generate environmental benefits through reduced greenhouse gas emissions. The case describes challenges facing this small agricultural biotechnology company, notably uneven enforcement of intellectual property in emerging market countries, and uncertainty regarding the provision and market value of carbon credits under international c...Starting at €8.20
-
Valuation of AirThread Connections, Teaching Note
Stafford, Erik; Heilprin, Joel L.Teaching Note HBS-4264-EFinanceTeaching note for case #4263.Starting at €0.00
-
Valuation of AirThread Connections (Spanish version)
Stafford, Erik; Heilprin, Joel L.Case HBS-413S06FinanceThis case can be used as a capstone valuation exercise for first-year MBA students in an introductory finance course. A senior associate in the business development group at American Cable Communications, one of the largest cable companies in the U.S., must prepare a preliminary valuation for acquiring AirThread Connections, a regional cellular provider. The acquisition would give American Cable access to wireless technology and the wireless spec...Starting at €8.20
-
Targanta Therapeutics: Hitting a Moving Target
Daemmrich, Arthur A.Case HBS-709002-EEntrepreneurshipThis case explores regulatory, product testing, and business strategy at Targanta Therapeutics, a biotech company preparing its first new drug application to the FDA. In October 2007, Mark Leuchtenberger, president and CEO of Targanta - which has just held a successful IPO - weighs options for the approximately ten month review period after the company submits to the Food and Drug Administration. The case reviews Targanta's origins and "de-riskin...Starting at €8.20